BSE Live
Apr 13, 16:01Prev. Close
1000.65
Open Price
990.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 13, 16:00Prev. Close
1000.00
Open Price
993.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1001.15 (40)
| Balance Sheet of Strides Pharma Science (in Rs. Cr.) | Dec 04 | |
| 15 mths | ||
| EQUITIES AND LIABILITIES | ||
| SHAREHOLDER'S FUNDS | ||
| Equity Share Capital | 33.76 | |
| Total Share Capital | 33.76 | |
| Reserves and Surplus | 204.36 | |
| Total Reserves and Surplus | 204.36 | |
| Total Shareholders Funds | 238.12 | |
| NON-CURRENT LIABILITIES | ||
| Long Term Borrowings | 164.75 | |
| Deferred Tax Liabilities [Net] | 13.43 | |
| Other Long Term Liabilities | 0.00 | |
| Long Term Provisions | 0.00 | |
| Total Non-Current Liabilities | 178.18 | |
| CURRENT LIABILITIES | ||
| Short Term Borrowings | 46.95 | |
| Trade Payables | 58.88 | |
| Other Current Liabilities | 1.35 | |
| Short Term Provisions | 17.85 | |
| Total Current Liabilities | 125.03 | |
| Total Capital And Liabilities | 541.33 | |
| ASSETS | ||
| NON-CURRENT ASSETS | ||
| Tangible Assets | 85.43 | |
| Intangible Assets | 6.83 | |
| Capital Work-In-Progress | 27.43 | |
| Other Assets | 0.00 | |
| Fixed Assets | 119.69 | |
| Non-Current Investments | 158.10 | |
| Deferred Tax Assets [Net] | 0.00 | |
| Long Term Loans And Advances | 0.00 | |
| Other Non-Current Assets | 0.00 | |
| Total Non-Current Assets | 277.79 | |
| CURRENT ASSETS | ||
| Current Investments | 0.00 | |
| Inventories | 27.03 | |
| Trade Receivables | 121.57 | |
| Cash And Cash Equivalents | 15.63 | |
| Short Term Loans And Advances | 80.33 | |
| OtherCurrentAssets | 18.98 | |
| Total Current Assets | 263.54 | |
| Total Assets | 541.33 | |
| OTHER ADDITIONAL INFORMATION | ||
| CONTINGENT LIABILITIES, COMMITMENTS | ||
| Contingent Liabilities | 68.69 | |
| CIF VALUE OF IMPORTS | ||
| Raw Materials | 62.32 | |
| Stores, Spares And Loose Tools | 0.00 | |
| Trade/Other Goods | 0.00 | |
| Capital Goods | 5.86 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||
| Expenditure In Foreign Currency | 19.19 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||
| Dividend Remittance In Foreign Currency | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||
| FOB Value Of Goods | 266.66 | |
| Other Earnings | 15.54 | |
| BONUS DETAILS | ||
| Bonus Equity Share Capital | 1.25 | |
| NON-CURRENT INVESTMENTS | ||
| Non-Current Investments Quoted Market Value | 0.37 | |
| Non-Current Investments Unquoted Book Value | 176.86 | |
| CURRENT INVESTMENTS | ||
| Current Investments Quoted Market Value | -- | |
| Current Investments Unquoted Book Value | -- |
18.03.2026
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
26.12.2025
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth